Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 2, 1996, Pages 361-368

  Lamond, John P ^a   Wang, Meizhi ^b   Kinsella, Timothy J ^a   Boothman, David A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

DNA repair; DNA Topo I complexes; PLDR; SLDR; Topoisomerase I

Indexed keywords

DNA; DNA TOPOISOMERASE; GYRASE INHIBITOR; TOPOTECAN;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG CONCENTRATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LETHALITY; MELANOMA; PRIORITY JOURNAL; RADIATION DOSE; X IRRADIATION;

EID: 0030248750     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00328-8     Document Type: Article

References (43)

1. 1. Avemann, K.; Knippers, R.; Koller, T. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell Biol. 8:3026-3034; 1988.
2. 2. Boothman, D. A. Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in chinese hamster embryo fibroblasts. Radiat. Res. 138:5121-5125; 1994.
3. 3. Boothman, D. A.; Fukunaga, N.; Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res. 54:4618-4626; 1994.
4. 4. Boothman, D. A.; Greer, S.; Pardee, A. B. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res. 47:5361-5367; 1987.
5. 5. Boothman, D. A.; Pardee, A. B. Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc. Natl. Acad. Sci. USA 86:4963-4967; 1989.
6. 6. Boothman, D. A.; Schlegel, R.; Pardee, A. B. Anticarcinogenic potential of DNA repair inhibitors. Mutat. Res. 202:393-411; 1989.
7. 7. Boothman, D. A.; Trask, D. K.; Pardee, A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res. 49:605-612; 1989.
8. 8. Boothman, D. A.; Wang, M.; Schea, R.; Burrows, H. L.; Strickfaden, S.; Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24:939-948; 1992.
9. 9. Boscia, R. E.; Korbut, T.; Holden, S. A.; Ara, G.; Teicher, B. A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FS aII C fibrosarcoma in vivo. Int. J. Cancer 53:118-123; 1993.
10. 10. Burris, H. A., III; Hanauske, A.-R.; Johnson, R. K.; Marshall, M. H.; Kuhn, J. G.; Hilsenbeck, S. G.; Von Hoff, D. D. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. 84:1816-1820; 1992.
11. 11. Del Bino, G.; Bruno, S.; Yi, P. N.; Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif. 25:537-548; 1992.
12. 12. Eng, W.; Facette, L.; Johnson, R. K.; Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:755-760; 1988.
13. 13. Falk, S. J.; Smith, P. J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol. 61:749-757; 1992.
14. 14. Giovanella, B. C.; Stehlin, J. S.; Wall, M. E.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048; 1989.
15. 15. Gottlieb, J. A.; Guarino, A. M.; Call, J. B. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54:461-470; 1970.
16. 16. Gottlieb, J. A.; Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 56:103-105; 1972.
17. 17. Grochow, L. B.; Rowinsky, E. K.; Johnson, R.; Ludeman, S.; Kaufmann, S. H.; McCabe, F. L.; Smith, B. R.; Hurowitz, L.; DeLisa, A.; Donehower, R. C.; Noe, O. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Disposit 20(5):706-713; 1992.
18. 18. Hall, E. J. Chemotherapeutic agents from the perspective of a radiation biologist. In: Hall, E. J., ed. Radiobiology for the radiolologist. Philadelphia, PA: J. B. Lippincott Co.; 1994:289-309.
19. 19. Hall, E. J. Repair of radiation damage and dose-rate effect. In: Hall, E. J., ed. Radiobiology for the radiolologist. Philadelphia, PA: J. B. Lippincott Co.; 1994:111-115.
20. 20. Hennequin, C.; Giocanti, N.; Balosso, J.; Favaudon, V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54:1720-1728; 1994.
21. 21. Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638; 1989.
22. 22. Hirabayashi, N.; Kim, R.; Nishiyama, M.; et al. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc. Am. Assoc. Cancer Res. (Abstr.) 33:436-; 1992.
23. 23. Hsaing, Y.-H; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082; 1989.
24. 24. Hsaing, Y.-H.; Liu, L. F. Identification of mammary DNA topoisomerase I as an intra cellular target of the anti cancer drug camptothecin. Cancer Res. 48:1722-1726; 1988.
25. 25. Husain, I.; Mohler, J. L.; Seigler, H. F.; Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:539-546; 1994.
26. 26. Hutson, P. R.; Kim, K.; Johnson, D.; Schiller, J. H. Pharmacodynamic evaluation of the response of extensive stage small cell lung cancer to topotecan. Proc. ASCO 14:460; 1995.
27. 27. Kim, J. H.; Kim, S. H.; Kolozsvary, A.; Khil, M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22:515-518; 1992.
28. 28. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and anti-tumor activity. J. Med. Chem. 34:98-107; 1991.
29. 29. Madden, K. R.; Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res. 52:525-532; 1992.
30. 30. Mattern, M. R.; Hoffman, G. A.; McCabe, F. L.; Johnson, R. K. Synergistic cell killing by ionizing radiation and the topoisomerase I inhibitor, Topotecan (SK & F 104864). Cancer Res. 51:5813-5816; 1991.
31. 31. Moertel, C. G.; Schutt, A. J.; Reitemeier, R. J. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56:95-101; 1972.
32. 32. Muggia, F. M.; Creaven, P. J.; Hansen, H. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother. Rep. 56:515-521; 1972.
33. 33. Musk, S. R.; Steele, G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br. J. Cancer 62:364-367; 1990.
34. 34. Recondo, G.; Abbruzzese, J.; Newman, B.; et al. A phase I trial of topotecan (topo) administered by a 24-h. infusion. (Abstr.) Proc. Am. Assoc. Cancer Res. 32:206; 1991.
35. 35. Roffler, S. K.; Chan, V.; Yeh, M. Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 54:1276-1285; 1994.
36. 36. Rowinski, E. K.; Sartorius, S.; Grochow, L. Phase I and pharmacological study of topotecan, a novel topoisomerase I inhibitor. J. Clin. Oncol. 10:647-656; 1992.
37. 37. Slichenmyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:271-291; 1993.
38. 38. Trask, D. K.; DiDonato, J. A.; Muller, M. T. Rapid detection and isolation of covalent DNA protein complexes: Application to topoisomerase I and II. EMBO J. 3:671-676; 1983.
39. 39. Trask, D. K.; Muller, M. T. Stabilization of type I topoisomerase-DNA covalent DNA/protein complexes: By actinomycin-D. Proc. Natl. Acad. Sci. USA 85:1417-1421; 1988.
40. 40. Van Der Zee, A. G.; Hollema, H.; de Jong, S.; Boonstra, H.; Gouw, A.; Willemsz, P. H.; Zijlstra, J. G.; De Vries, E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51:5915-5920; 1991.
41. 41. Wall, M. E.; Wani, M. C.; Cook, C. E.; Plumer, K. H.; McPhail, A. T.; Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:3888-3890; 1966.
42. 42. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 54:665-697; 1985.
43. 43. Zhang, H.; D'Arpa, P.; Liu, L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells (Cold Spring Harbor) 2:23-27; 1990.